As the world yearns for a return to normal life after more than a year of living through the pandemic, countries are racing to deliver vaccines that should slow — and hopefully stop — the spread of the coronavirus.
Successfully doing so will depend on an array of factors, from manufacturing and transporting billions of doses, ensuring that rich nations don’t monopolize the world’s vaccine supply, and, crucially, actually getting doses into people’s arms.
The charts and maps below will update to show the most recent data on the largest vaccination rollout in history, in the US and across the globe.
There are notable differences from state to state in how quickly the vaccines are being given to people.
The first two vaccines approved for emergency use in the US, developed by the companies Pfizer/BioNTech and Moderna, are designed to be given in two doses several weeks apart. The Johnson & Johnson vaccine authorized for use in late February requires only one dose. So to vaccinate everyone in the US will eventually mean giving somewhere between 100 and 200 doses per 100 people across each state and territory — or a total of between 330 million and 660 million doses for the entire nation. It’s a huge logistic challenge.
US vaccine rollout began more slowly than expected. The Trump administration set a goal of giving 20 million vaccinations by the end of 2020. That target was not reached until late January. In early March, President Joe Biden said the US would have enough vaccines for all adults by the end of May — two months earlier than his administration had previously planned. Still, there are concerns that the vaccination drive is leaving poorer people and communities of color behind.
Search or navigate through this table to find how your state or territory is doing on these key measures of vaccine rollout.
Vaccine rollout timeline
This chart shows the number of vaccines administered per 100 people for each state from the beginning of 2021. The top three states and US national numbers are highlighted. Type the name of any other state or US territory into the search bar and select to add to the chart.
This chart shows the daily number of vaccine doses given to people across the nation from the start of 2021. Because of spikes in the data due to lags in reporting, the line showing the 7-day rolling average of doses given gives a clearer idea of whether the rollout is accelerating or slowing.
Vaccine rollout by nation
More countries appear on this map showing vaccine doses given per 100 people because these numbers are more widely reported.
The US is ahead of most other nations in vaccine rollout. But among major nations Israel has been the early leader.
Search or navigate through this table to see how each nation is doing. It reveals that some nations have taken different strategies: The UK, for instance, decided to give as many people as possible an initial dose, delaying their second shots.
Vaccine rollout timeline
This chart shows the number of vaccines administered per 100 people for each country from the beginning of 2021. Type the name of any nation into the search bar and select to compare its timeline with the US and the other top three countries leading vaccine rollout worldwide. Only countries that have started their vaccination campaigns will appear.
This chart shows the reported daily number of vaccine doses given to people across the world. Because of spikes due to lags in reporting, the line showing the 7-day rolling average of doses given gives a clearer idea of whether the rollout is accelerating or slowing.
Status of leading vaccines
This table documents the status of leading COVID-19 vaccines, showing authorizations for use in the US and other seleceted markets, plus prices from information on purchase agreements compiled by UNICEF, where available.
The vaccines from Pfizer/BioNTech and Moderna, with clinical trial results indicating that they are more than 90% effective in preventing disease, are based on a new technology that delivers a sequence of RNA that makes our own cells produce viral proteins, triggering an immune response.
The drawback is that these vaccines are more expensive than those made by splicing genetic material from the coronavirus into a disabled version of another virus, such as those produced by the Anglo-Swedish company AstraZeneca, based on research from Oxford University, Johnson & Johnson, and Russia’s Gamaleya Research Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a longstanding approach to making vaccines, or subunits of proteins from the virus.
Jeremy Singer-Vine contributed reporting for this story.